Rapamycin (Sirolimus) Monitoring Schedule: Labs & Exams
Complete rapamycin (sirolimus) monitoring schedule covering blood trough levels, lipid panels, CBC, renal function, glucose, and imaging exams for both transplant and off-label longevity use.
Rapamycin (Sirolimus) Off-Label Uses with Evidence Levels
A clinical review of rapamycin (sirolimus) off-label applications, from longevity and immune aging to skin rejuvenation, with evidence grading for each use case.
Rapamycin (Sirolimus) Safety in Older Adults (50 to 64): What the Evidence Shows
A guide to rapamycin (sirolimus) safety for adults aged 50 to 64, covering dose protocols, side effects, lab monitoring, drug interactions, and trial data from PEARL and other studies.
Rapamycin (Sirolimus) Patent Field & Generic Timeline
A clinician-grade review of the sirolimus patent history, generic availability, and what the expiration of key patents means for off-label longevity prescribing and cost.
Rapamycin (Sirolimus) Pediatric Dosing for Children Under 12
Evidence-based guide to sirolimus (rapamycin) dosing in children under 12, covering weight-based protocols, therapeutic drug monitoring, off-label indications, and safety considerations.
Rapamycin (Sirolimus) Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion
A clinician-grade review of sirolimus pharmacokinetics covering oral bioavailability, tissue distribution, CYP3A4 metabolism, 62-hour half-life, and dosing implications for transplant and off-label longevity use.
Rapamycin (Sirolimus) Regulatory Status: US, EU, Canada, and UK Approvals Explained
A physician-level review of sirolimus regulatory approvals across the US, EU, Canada, and the UK, covering transplant indications, off-label longevity use, and prescribing pathways.
Rapamycin (Sirolimus) Dosing for Young Adults (18 to 29): What the Evidence Actually Shows
Evidence-based guide to rapamycin (sirolimus) dosing considerations for adults aged 18-29, covering off-label longevity protocols, fertility risks, immune effects, and monitoring requirements.
Alprostadil (Caverject/MUSE) Compounding Legal Status
A detailed regulatory guide to alprostadil compounding under FDA sections 503A and 503B, covering Caverject and MUSE approval history, trimix legality, outsourcing facility rules, and state-level pharmacy requirements.
Alprostadil (Caverject/MUSE): EMA vs FDA Regulatory Approach
A detailed comparison of how the FDA and EMA regulate alprostadil (Caverject, MUSE, Vitaros), including approval timelines, labeled indications, safety monitoring, and post-market requirements.
AndroGel Compounding Legal Status: FDA Rules, 503B Outsourcing, and What Patients Need to Know
A clinical breakdown of AndroGel's FDA approval history, current compounding legal status under 503A and 503B pathways, label requirements, and safety considerations for compounded testosterone gel.
AndroGel EMA vs FDA Approach: How Two Regulators Handle Testosterone Gel Differently
A detailed comparison of how the FDA and EMA regulate AndroGel (testosterone gel), including approval history, cardiovascular safety reviews, label restrictions, and post-market surveillance differences.
AndroGel FAERS Safety Signals: FDA Post-Market Surveillance Data and What It Means
A clinical review of AndroGel (testosterone gel) safety signals reported through the FDA Adverse Event Reporting System (FAERS), including cardiovascular events, polycythemia, transference risk, and regulatory label changes.
AOD-9604: EMA vs FDA Regulatory Approach
How the FDA and EMA treat AOD-9604 (HGH fragment 176-191) differently. Covers approval status, compounding access under 503A, European classification, clinical trial history, and safety data gaps.
AOD-9604 Label Updates 2020-2026: FDA Status, Safety Signals, and Regulatory Timeline
A complete regulatory timeline of AOD-9604 (HGH fragment 176-191) from 2020 through 2026, covering FDA bulk drug substance evaluations, compounding pharmacy oversight, warning letters, and safety data.
AOD-9604 Legal and Patent Challenges: FDA Status, Regulatory History, and Compounding Access
AOD-9604 (HGH fragment 176-191) has never received FDA approval. This article examines its patent history, FDA warning letters, regulatory classification disputes, and the legal field for compounding pharmacies.
AOD-9604 Pipeline and Next-Gen: FDA Status, Safety, and What Comes Next
AOD-9604 remains unapproved by the FDA with no active IND or NDA on file. This article covers its regulatory history, compounding status, safety data, and whether next-generation peptide fat-loss agents will surpass it.
BPC-157 FDA Approval History: Current Regulatory Status and What It Means
BPC-157 has never received FDA approval. Learn about its regulatory history, FDA enforcement actions, compounding pharmacy status, and what the science actually shows about this peptide.
BPC-157 Global Regulatory Status: FDA Classification, International Rules, and What Patients Should Know
A breakdown of BPC-157 regulatory status worldwide, including FDA stance, EMA position, compounding pharmacy access, and clinical trial evidence as of 2026.
BPC-157 Legal & Patent Challenges: FDA Status, Compounding Rules, and What Patients Should Know
A guide to BPC-157's regulatory status, FDA enforcement actions, patent barriers, and the legal framework governing its compounding and clinical use in the United States.
BPC-157 FAERS Safety Signals: What FDA Adverse-Event Data Reveal
An evidence-based review of BPC-157 in the FDA Adverse Event Reporting System (FAERS), covering safety signals, regulatory status, compounding pharmacy risks, and what clinicians should know.
Vyleesi (Bremelanotide) Label Updates 2020 to 2026: FDA Safety Revisions and Post-Market Changes
A complete timeline of Vyleesi (bremelanotide) FDA label updates from 2020 through 2026, covering safety revisions, boxed warning changes, post-market study requirements, and prescribing information modifications.
Vyleesi (Bremelanotide) Legal and Patent Challenges
A clinical review of Vyleesi's regulatory history, patent disputes, FDA labeling restrictions, and post-market safety signals, with cited trial data and guideline references.
Vyleesi (Bremelanotide) Pipeline, FDA Status, and Next-Generation Melanocortin Therapies
Complete regulatory profile of Vyleesi (bremelanotide): FDA approval history, label details, post-market safety data, and the melanocortin receptor pipeline beyond HSDD.
Vyleesi (Bremelanotide) FAERS Safety Signals: Post-Market Surveillance Data
A clinical review of Vyleesi (bremelanotide) safety signals reported to the FDA Adverse Event Reporting System (FAERS), including nausea, blood pressure changes, hyperpigmentation, and injection site reactions.
Cialis Compounding Legal Status: FDA Rules, 503A/503B Pathways, and What Patients Should Know
A clinical review of tadalafil (Cialis) compounding legality under FDA 503A and 503B frameworks, patent expiry implications, and how patients can safely access compounded tadalafil in 2026.
Cialis (Tadalafil): EMA vs. FDA Regulatory Approaches Compared
A side-by-side comparison of how the FDA and EMA approved, labeled, and monitor tadalafil (Cialis), including indication scope, dosing, safety signals, and post-market surveillance differences.
Cialis (Tadalafil) Global Regulatory Status: FDA Approval, EMA Authorization, and Post-Market Safety
A complete regulatory history of Cialis (tadalafil), covering FDA approval, EMA authorization, generic entry, label updates, and global post-market surveillance data.
CJC-1295: EMA vs FDA Regulatory Approach
How the FDA and EMA differ in their regulatory treatment of CJC-1295 (modified GRF 1-29), including approval status, compounding oversight, and safety signals.
CJC-1295 FDA Approval History: Why This Peptide Was Never Approved
CJC-1295 has never received FDA approval. Review the full regulatory timeline, clinical trial data from Teichman et al., compounding pharmacy status, and current legal standing of this GHRH analog.
CJC-1295 Label Updates 2020 to 2026: FDA Actions, Compounding Status, and Safety Notices
A complete regulatory timeline of CJC-1295 modified GRF from 2020 through 2026, covering FDA bulk drug substance decisions, compounding pharmacy guidance, and safety communications.
CJC-1295 Legal and Patent Challenges: FDA Status, Compounding Rules, and What Patients Need to Know
CJC-1295 has never received FDA approval. This article covers its regulatory history, patent landscape, compounding legality under 503A/503B frameworks, and the clinical trial data that shaped its current status.
CJC-1295 Pipeline and Next-Gen Growth Hormone Secretagogues
CJC-1295 has no FDA approval. Learn about its regulatory status, compounding pharmacy sourcing, clinical trial data, safety signals, and what next-generation GH secretagogues may replace it.
CJC-1295 FAERS Safety Signals: What FDA Adverse Event Data Reveals
CJC-1295 has never received FDA approval. Review the available FAERS adverse event data, clinical trial safety findings, and the regulatory actions shaping access to this compounded GHRH analog.
Trulicity (Dulaglutide) FDA Approval History: Timeline, Label Changes, and Safety Updates
Complete FDA approval history of Trulicity (dulaglutide), including original 2014 approval, CVOT-driven label expansions, boxed warning details, and post-market safety signals from FAERS and Sentinel.
Trulicity (Dulaglutide) Global Regulatory Status
A complete regulatory overview of Trulicity (dulaglutide), covering FDA approval, EMA authorization, label expansions, REWIND cardiovascular data, post-market safety signals, and current global market access.
Trulicity Label Updates 2020 to 2026: A Complete FDA Regulatory Timeline for Dulaglutide
Trulicity side effects and safety: a Boxed Warning for thyroid C-cell tumors, plus pancreatitis, anaphylaxis, kidney injury, ileus and nausea warnings.
Avodart (Dutasteride): EMA vs FDA Regulatory Approach Compared
A side-by-side comparison of how the FDA and EMA regulate dutasteride (Avodart), including approval timelines, label differences, post-market safety actions, and what the divergence means for prescribers.
Avodart (Dutasteride) Global Regulatory Status: FDA Approval, EMA Authorization, and Post-Market Safety
A comprehensive review of dutasteride (Avodart) regulatory approvals worldwide, including FDA labeling, EMA authorization, post-market surveillance data, and current prescribing considerations.
Avodart (Dutasteride) FDA Label Updates 2020-2026: What Changed and Why It Matters
A comprehensive review of every FDA label change for Avodart (dutasteride) from 2020 through 2026, including updated safety warnings, post-market surveillance findings, and clinical guidance for prescribers and patients.
Avodart (Dutasteride): Legal and Patent Challenges
A regulatory deep-dive into Avodart's FDA approval history, patent litigation, generic entry battles, and post-market safety label changes for dutasteride.
Enclomiphene Citrate FDA Approval History
A detailed regulatory history of enclomiphene citrate, including FDA review timelines, clinical trial data, NDA rejections, and the current compounding field.
Enclomiphene Citrate Label Updates 2020 to 2026: FDA Status, Compounding Rules, and Safety Signals
A clinical review of enclomiphene citrate's regulatory trajectory from 2020 through 2026, covering FDA approval status, compounding pharmacy access, label requirements, and post-market safety data.
Enclomiphene Citrate Legal & Patent Challenges
A clinical review of enclomiphene citrate's regulatory history, patent disputes, FDA status, and the legal factors shaping its availability for male hypogonadism treatment.
Epitalon FDA Approval History
Epitalon (epithalon tetrapeptide, Ala-Glu-Asp-Gly) has never received FDA approval. This article covers its regulatory status, the Russian clinical literature behind it, and what patients should know before considering this research peptide.
Epitalon Pipeline and Next-Gen Research: FDA Status, Safety Data, and What Comes After the Tetrapeptide
Epitalon has no FDA approval and remains a research-only peptide. This article covers its regulatory status, published safety signals, clinical trial gaps, and the next-generation telomerase-targeting compounds in early development.
Finasteride EMA vs FDA Approach: How Two Regulators Handle the Same Drug Differently
A detailed comparison of how the FDA and EMA regulate finasteride, covering approval history, label warnings, post-market surveillance, and what the procedural divergence means for prescribers and patients.
Finasteride Global Regulatory Status
A comprehensive review of finasteride's regulatory approvals worldwide, including FDA history, EMA authorization, label updates, post-market safety signals, and current prescribing requirements across major markets.
Addyi (Flibanserin) Compounding Legal Status: FDA Rules, REMS, and 503A/503B Limits
Is compounding flibanserin legal? A clinical breakdown of Addyi's FDA approval history, REMS requirements, 503A and 503B pharmacy rules, and what prescribers and patients need to know about compounded flibanserin access.
Addyi (Flibanserin): EMA vs FDA Regulatory Approaches Compared
A clinical comparison of how the FDA approved Addyi (flibanserin) for HSDD while the EMA declined authorization, including trial data, safety requirements, and post-market changes.
Addyi (Flibanserin) FAERS Safety Signals: Post-Market Surveillance Data and Label Updates
A clinical review of flibanserin (Addyi) safety signals reported through the FDA Adverse Event Reporting System (FAERS), including syncope, hypotension, and CNS depression data from post-market surveillance.
GHK-Cu FDA Approval History: Regulatory Status of Copper Tripeptide
GHK-Cu has never received FDA approval as a drug. Learn the full regulatory history of copper tripeptide GHK-Cu, its compounding pharmacy status under Section 503A, and what the science says about safety.
GHK-Cu Label Updates 2020 to 2026: FDA Compounding Status, Safety Reviews, and Regulatory Changes
A comprehensive review of GHK-Cu (copper tripeptide) regulatory developments from 2020 through 2026, including FDA compounding oversight, bulk drug substance evaluations, and safety data.
GHK-Cu Legal & Patent Challenges: FDA Status, Compounding Rules, and Regulatory Risk
A clinical breakdown of GHK-Cu's regulatory classification, patent history, FDA enforcement actions against compounding pharmacies, and what prescribers need to know about legal compliance.
GHK-Cu FAERS Safety Signals: What FDA Adverse-Event Data Reveal About Copper Peptide
GHK-Cu has no FDA-approved label and virtually no FAERS footprint. Here is what post-market surveillance data do and do not tell us about copper tripeptide safety.
Accutane Compounding Is Illegal: FDA and iPLEDGE Rules
Isotretinoin cannot be legally compounded under 503A or 503B rules. iPLEDGE and Category X teratogenicity make compounded Accutane prohibited and unnecessary.
Accutane (Isotretinoin) Pipeline and Next-Gen Formulations: FDA History, Safety Updates, and Future Directions
A clinical review of isotretinoin's regulatory history, current FDA label requirements, iPLEDGE program updates, next-generation retinoid pipeline candidates, and post-market safety surveillance data.
Jatenzo Label Updates 2020 to 2026: FDA Safety Changes, REMS, and Prescribing Revisions
A comprehensive timeline of every FDA label change to Jatenzo (oral testosterone undecanoate) from initial approval through 2026, including REMS requirements, cardiovascular warnings, and dosing revisions.
Jatenzo Legal and Patent Challenges: FDA Approval, Label Disputes, and Post-Market Surveillance
A clinical review of Jatenzo (oral testosterone undecanoate) covering its FDA approval history, patent litigation, labeling requirements, REMS considerations, and ongoing legal challenges facing Tolmar.
Jatenzo Pipeline and Next-Gen Oral Testosterone: FDA Status, Label Updates, and What Comes Next
A clinical review of Jatenzo (oral testosterone undecanoate), its FDA approval history, current label, post-market safety data, and the next-generation oral TRT pipeline.